Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.
J Neurooncol
; 148(2): 373-379, 2020 Jun.
Article
in En
| MEDLINE
| ID: mdl-32409944
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
Bevacizumab
/
Antineoplastic Agents, Immunological
/
Glioma
/
Neoplasm Recurrence, Local
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Neurooncol
Year:
2020
Type:
Article
Affiliation country:
Germany